Single-cell analysis based dissection of clonality in myelofibrosis.
Elena MylonasKenichi YoshidaMareike FrickKaja HoyerFriederike ChristenJaspal KaedaMatthias ObenausDaniel NoerenbergCornelius HennchWilly ChanYotaro OchiYuichi ShiraishiYusuke ShiozawaThorsten ZenzChristopher C OakesBirgit SawitzkiMichaela SchwarzLars BullingerPhilipp le CoutreMatthew J J Rose-ZerilliSeishi OgawaFrederik DammPublished in: Nature communications (2020)
Cancer development is an evolutionary genomic process with parallels to Darwinian selection. It requires acquisition of multiple somatic mutations that collectively cause a malignant phenotype and continuous clonal evolution is often linked to tumor progression. Here, we show the clonal evolution structure in 15 myelofibrosis (MF) patients while receiving treatment with JAK inhibitors (mean follow-up 3.9 years). Whole-exome sequencing at multiple time points reveal acquisition of somatic mutations and copy number aberrations over time. While JAK inhibition therapy does not seem to create a clear evolutionary bottleneck, we observe a more complex clonal architecture over time, and appearance of unrelated clones. Disease progression associates with increased genetic heterogeneity and gain of RAS/RTK pathway mutations. Clonal diversity results in clone-specific expansion within different myeloid cell lineages. Single-cell genotyping of circulating CD34 + progenitor cells allows the reconstruction of MF phylogeny demonstrating loss of heterozygosity and parallel evolution as recurrent events.
Keyphrases
- copy number
- single cell
- genome wide
- mitochondrial dna
- rna seq
- dna methylation
- high throughput
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- papillary thyroid
- acute myeloid leukemia
- prognostic factors
- bone marrow
- poor prognosis
- peritoneal dialysis
- gene expression
- immune response
- patient reported outcomes
- squamous cell carcinoma
- long non coding rna
- smoking cessation